Predictive value of immunotherapy-induced inflammation indexes: dynamic changes in patients with nasopharyngeal carcinoma receiving immune checkpoint inhibitors

References

• Chen YP, Chan ATC, Le QT, et al. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):1–11. doi: 10.1016/S0140-6736(19)30956-0.
   PubMed Web of Science ®Google Scholar
• Xu T, Tang J, Gu M, et al. Recurrent nasopharyngeal carcinoma: a clinical dilemma and challenge. Curr Oncol. 2013;20(5):e406-19–e419. doi: 10.3747/co.20.1456.
   PubMed Web of Science ®Google Scholar
• Xu JY, Wei XL, Wang YQ, et al. Current status and advances of immunotherapy in nasopharyngeal carcinoma. Ther Adv Med Oncol. 2022;14:175883592210962. doi: 10.1177/17588359221096214.
   Web of Science ®Google Scholar
• Killock D. Camrelizumab efficacious in NPC. Nat Rev Clin Oncol. 2021;18(9):542–542. doi: 10.1038/s41571-021-00542-9.
   PubMed Web of Science ®Google Scholar
• Liu MZ, Tang LL, Zong JF, et al. Evaluation of sixth edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement. Int J Radiat Oncol Biol Phys. 2008;70(4):1115–1123. doi: 10.1016/j.ijrobp.2007.07.2353.
   PubMed Web of Science ®Google Scholar
• Yan C, Shen DS, Chen XB, et al. CT-based radiomics nomogram for prediction of progression-free survival in locoregionally advanced nasopharyngeal carcinoma. Cancer Manag Res. 2021;13:6911–6923. doi: 10.2147/CMAR.S325373.
   PubMed Web of Science ®Google Scholar
• Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol. 2015;12(10):584–596. doi: 10.1038/nrclinonc.2015.105.
   PubMed Web of Science ®Google Scholar
• Diakos CI, Charles KA, McMillan DC, et al. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–e503. doi: 10.1016/S1470-2045(14)70263-3.
   PubMed Web of Science ®Google Scholar
• Ding P, Guo H, Sun C, et al. Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study. BMC Gastroenterol. 2022;22(1):121. doi: 10.1186/s12876-022-02199-9.
   PubMed Web of Science ®Google Scholar
• Qi WX, Xiang Y, Zhao S, et al. Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab. Cancer Immunol Immunother. 2021;70(11):3199–3206. doi: 10.1007/s00262-021-02926-3.
   PubMed Web of Science ®Google Scholar
• Fornarini G, Rebuzzi SE, Banna GL, et al. Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort. ESMO Open. 2021;6(3):100118. doi: 10.1016/j.esmoop.2021.100118.
   PubMed Web of Science ®Google Scholar
• Shang J, Han X, Zha H, et al. Systemic immune-inflammation index and changes of neutrophil-lymphocyte ratio as prognostic biomarkers for patients with pancreatic cancer treated with immune checkpoint blockade. Front Oncol. 2021;11:585271. doi: 10.3389/fonc.2021.585271.
   PubMed Web of Science ®Google Scholar
• Wu X, Han R, Zhong Y, et al. Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma. Cancer Cell Int. 2021;21(1):356. doi: 10.1186/s12935-021-02072-x.
   PubMed Web of Science ®Google Scholar
• Bilen MA, Martini DJ, Liu Y, et al. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. Cancer. 2019;125(1):127–134. doi: 10.1002/cncr.31778.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang C, Peng Z, et al. Association of lymphocyte-to-monocyte ratio with survival in advanced gastric cancer patients treated with immune checkpoint inhibitor. Front Oncol. 2021;11:589022. doi: 10.3389/fonc.2021.589022.
   PubMedGoogle Scholar
• Zeng X, Liu G, Pan Y, et al. Development and validation of immune inflammation-based index for predicting the clinical outcome in patients with nasopharyngeal carcinoma. J Cell Mol Med. 2020;24(15):8326–8349. doi: 10.1111/jcmm.15097.
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259. doi: 10.1158/1078-0432.CCR-04-0713.
   PubMed Web of Science ®Google Scholar
• De Giorgi U, Procopio G, Giannarelli D, et al. Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab. Clin Cancer Res. 2019;25(13):3839–3846. doi: 10.1158/1078-0432.CCR-18-3661.
   PubMed Web of Science ®Google Scholar
• Stühler V, Herrmann L, Rausch S, et al. Role of the systemic immune-inflammation index in patients with metastatic renal cell carcinoma treated with first-line ipilimumab plus nivolumab. Cancers (Basel). 2022; 14(12):2972. doi: 10.3390/cancers14122972.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Matsuyama H, Matsumoto H, et al. Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma. Jpn J Clin Oncol. 2020;50(2):214–220. doi: 10.1093/jjco/hyz168.
   PubMed Web of Science ®Google Scholar
• Hwang M, Canzoniero JV, Rosner S, et al. Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. J Immunother Cancer. 2022;10(6):e004688. doi: 10.1136/jitc-2022-004688.
   PubMed Web of Science ®Google Scholar
• Ayers KL, Ma M, Debussche G, et al. A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers. BMC Cancer. 2021;21(1):441. doi: 10.1186/s12885-021-08194-9.
   PubMed Web of Science ®Google Scholar
• Choi WM, Kim JY, Choi J, et al. Kinetics of the neutrophil-lymphocyte ratio during PD-1 inhibition as a prognostic factor in advanced hepatocellular carcinoma. Liver Int. 2021;41(9):2189–2199. doi: 10.1111/liv.14932.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Yatsuda J, Shimokawa M, et al. Prognostic value of pre-treatment risk stratification and post-treatment neutrophil/lymphocyte ratio change for pembrolizumab in patients with advanced urothelial carcinoma. Int J Clin Oncol. 2021;26(1):169–177. doi: 10.1007/s10147-020-01784-w.
   PubMed Web of Science ®Google Scholar
• Iwasa YI, Yokota Y, Kitoh R, et al. Factors affecting nivolumab therapy outcome in patients with head and neck cancer: a single-center analysis. Oncology. 2022;100(4):203–211. doi: 10.1159/000522035.
   PubMed Web of Science ®Google Scholar
• Nakamura N, Kinami S, Fujita J, et al. Chronological changes in neutrophil/lymphocyte ratio in advanced gastric cancer patients treated with nivolumab: a report of nine cases. Asian Pac J Cancer Prev. 2020;21(10):2955–2960. doi: 10.31557/APJCP.2020.21.10.2955.
   PubMedGoogle Scholar
• Chen Y, Sun J, Hu D, et al. Predictive value of pretreatment lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio in the survival of nasopharyngeal carcinoma patients. Cancer Manag Res. 2021;13:8767–8779. doi: 10.2147/CMAR.S338394.
   PubMed Web of Science ®Google Scholar
• Yuan X, Feng H, Huang H, et al. Systemic immune-inflammation index during treatment predicts prognosis and guides clinical treatment in patients with nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2023;149(1):191–202. doi: 10.1007/s00432-022-04506-z.
   PubMed Web of Science ®Google Scholar
• Rebuzzi SE, Buti S, Sbrana A, et al. Baseline lymphocyte to monocyte ratio (LMR) and systemic inflammation index (SII) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: preliminary results of the meet-URO 15 (I-BIO-REC) study. J Clin Oncol. 2020;38(6_suppl):751–751. doi: 10.1200/JCO.2020.38.6_suppl.751.
   Web of Science ®Google Scholar
• Du F, Qiu Z, Ai W, et al. Blood tests predict the therapeutic prognosis of anti-PD-1 in advanced biliary tract cancer. J Leukoc Biol. 2021;110(2):327–334. doi: 10.1002/JLB.5MA1220-631R.
   PubMed Web of Science ®Google Scholar
• Failing JJ, Yan Y, Porrata LF, et al. Lymphocyte-to-monocyte ratio is associated with survival in pembrolizumab-treated metastatic melanoma patients. Melanoma Res. 2017;27(6):596–600. doi: 10.1097/CMR.0000000000000404.
   PubMed Web of Science ®Google Scholar
• Sekine K, Kanda S, Goto Y, et al. Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer. Lung Cancer. 2018;124:179–188. doi: 10.1016/j.lungcan.2018.08.012.
   PubMed Web of Science ®Google Scholar
• Prelaj A, Rebuzzi SE, Pizzutilo P, et al. EPSILoN: a prognostic score using clinical and blood biomarkers in advanced non-small-cell lung cancer treated with immunotherapy. Clin Lung Cancer. 2020;21(4):365–377.e5. doi: 10.1016/j.cllc.2019.11.017.
   PubMed Web of Science ®Google Scholar
• Jiang L, Luan Y, Miao X, et al. Platelet releasate promotes breast cancer growth and angiogenesis via VEGF-integrin cooperative signalling. Br J Cancer. 2017;117(5):695–703. doi: 10.1038/bjc.2017.214.
   PubMed Web of Science ®Google Scholar
• Menter DG, Kopetz S, Hawk E, et al. Platelet “first responders” in wound response, cancer, and metastasis. Cancer Metastasis Rev. 2017;36(2):199–213. doi: 10.1007/s10555-017-9682-0.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Cassatella MA, Costantini C, et al. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol. 2011;11(8):519–531. doi: 10.1038/nri3024.
   PubMed Web of Science ®Google Scholar
• Di Mitri D, Toso A, Chen JJ, et al. Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. Nature. 2014;515(7525):134–137. doi: 10.1038/nature13638.
   PubMed Web of Science ®Google Scholar
• Goto W, Kashiwagi S, Asano Y, et al. Predictive value of lymphocyte-to-monocyte ratio in the preoperative setting for progression of patients with breast cancer. BMC Cancer. 2018;18(1):1137. doi: 10.1186/s12885-018-5051-9.
   PubMedGoogle Scholar
• Olingy CE, Dinh HQ, Hedrick CC. Monocyte heterogeneity and functions in cancer. J Leukoc Biol. 2019;106(2):309–322. doi: 10.1002/JLB.4RI0818-311R.
   PubMed Web of Science ®Google Scholar